Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

Oculis Holding AG (Nasdaq: OCS; XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company, has issued registered ordinary shares of ...

Shares of Calvin Klein-owner PVH Corp and genetic testing company Illumina fell on Tuesday after China placed the two ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Leerink Partners maintained an Outperform rating on Arvinas Inc. (NASDAQ:ARVN) but reduced the price target from $62.00 to ...

Leerink Partners analyst Thomas Smith adjusted the price target for 89bio Inc . (NASDAQ:ETNB) to $37 from $34, while ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce ...

Leerink Partners analyst David Risinger noted the significant concern about the likelihood of success of TX45 in PH-HFpEF following the termination of Eli Lilly (NYSE:LLY)'s study. However ...

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report), with a ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on Surgery Partners (SGRY – Research Report), with a price target of ...

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...